F-18 Tetrafluoroborate PET/CT to find recurrent or residual differentiated thyroid cancer
Official title: F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer
Run by Ankara University · NCT07436455 · Data updated 2026-11-12
This test will see if F-18 Tetrafluoroborate PET/CT finds recurrent or residual differentiated thyroid cancer better than standard F-18 FDG PET/CT in adults who had surgery and radioactive iodine and now have rising thyroglobulin or anti-thyroglobulin.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Ankara University Academic / other |
| Locations | 2 sites (Ankara, Ankara and 1 other locations) |
| Status | Recruiting |
| Started | November 1, 2025 |
| Main results expected | August 1, 2026 |
| Study ends | October 1, 2026 |
| Registry record updated | February 27, 2026 |
| Trial ID | NCT07436455 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (≥18) who had surgery and radioactive iodine for differentiated thyroid cancer, now have elevated serum Tg and/or ATg, negative or equivocal I-131 whole-body scans, a Karnofsky performance status ≥50, and can give informed consent.
✕Probably not a fit
Patients under 18, pregnant or breastfeeding individuals, or those without elevated Tg/ATg or with clear findings on standard imaging are unlikely to benefit from this imaging comparison.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional imaging study enrolls adults with differentiated thyroid cancer who have had surgery and radioactive iodine but now show rising serum thyroglobulin or anti-thyroglobulin and negative or equivocal I-131 whole-body scans. Participants undergo F-18 Tetrafluoroborate (TFB) PET/CT imaging and results are compared with standard F-18 FDG PET/CT and conventional imaging (neck ultrasound, thorax CT) for lesion detection. F-18 TFB is taken up via the sodium-iodide symporter (NIS) in thyroid cells, a mechanism similar to I-131 but with PET imaging sensitivity. The study aims to determine whether F-18 TFB improves detection of thyroid cancer lesions that other imaging misses.
Why it matters
Potential benefit: If successful, the technique could detect recurrent or residual disease more accurately and earlier, helping doctors choose the right follow-up or treatment.
How similar studies have gone: Previous small studies have shown F-18 TFB is superior to I-131 whole-body scans and have reported promising lesion detection versus FDG PET/CT, but larger direct comparative data remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Having undergone surgery for differentiated thyroid cancer and received radioactive iodine therapy * Being evaluated for lesion detection due to elevated serum Tg and/or ATg levels during post-treatment follow-up * Negative or equivocal I-131 whole-body scan findings * Karnofsky Performance Status ≥ 50 (or equivalent Eastern Cooperative Oncology Group \[ECOG\]/World Health Organization \[WHO\] performance status) * Giving written informed consent Exclusion Criteria: * Age under 18 years * Pregnancy or breastfeeding * Failure to provide written informed consent
Where it's running
-
Ankara University Medical School Nuclear Medicine Department
Ankara, Ankara, Turkey (Türkiye) Recruiting -
Hacettepe University Medical School Nuclear Medicine Department
Ankara, Ankara, Turkey (Türkiye) Recruiting
Study contacts
- Principal investigator: Mine Araz, Assoc.Prof. — Ankara University Medical School Nuclear Medicine Department
- Study coordinator: Mine Araz, Assoc.Prof.Dr.
- Email: minesoylu@yahoo.com
- Phone: +905326667313
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
MRG003 added to ongoing treatment after progression in EGFR-positive advanced thyroid cancer
In this study, researchers test whether adding MRG003 to a patient’s current thyroid cancer treatment can shrink tumors for those whose cancer initially responded but later progressed.
-
Selective coverage radiotherapy vs. full coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer
This trial tests whether covering only the tumor-affected area with radiation is as effective as full-area coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer, while aiming to reduce side effects and improve quality of life.
-
Trop-2 Targeted PET/CT for Recurrent and Metastatic Thyroid Cancer
This study tests whether a Trop-2 targeted PET/CT scan can better detect recurrent or metastatic thyroid cancer in adults than another PET/CT scan (FAPI).
-
WeChat-supported neck exercises after thyroidectomy
A telehealth program using a WeChat mini program tests if guided neck exercises after thyroid surgery help early recovery and quality of life.
-
Pralsetinib Drug Interaction Study in RET Fusion/MUTATION Positive Solid Tumors
This trial tests whether pralsetinib changes how the body processes certain medicines in adults with RET fusion- or mutation-positive advanced solid tumors.
-
AI chatbot to guide thyroid cancer patients through perioperative education
A new AI chatbot is being tested to see if it helps thyroid cancer patients better prepare for discharge, recover well, and stay engaged in their care compared with traditional education.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.